Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.80 |
| ▸ | ITGAV | P06756 | 14/20 | 0.80 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.80 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.80 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.80 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176988 | 1.00 | ITGB3 (0.80) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL7260158 | 0.97 | ITGB3 (0.76) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL7259087 | 0.97 | ITGB3 (0.75) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6176461 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6176936 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6176963 | 0.89 | ITGB3 (1.00) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL7264806 | 0.86 | ITGB3 (0.94) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL7264797 | 0.86 | ITGB3 (0.94) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL7264202 | 0.84 | ITGB3 (0.70) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL13170293 | 0.83 | ITGB3 (0.87) | ITGB3ITGAVITGB1ITGB6ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | ITGB3 82/4885ITGAV 146/4885ITGB1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.